In 2023, Germany led the European Genito Urinary System and Sex Hormones market with sales reaching 806.3 million euros, showcasing a 0.61% increase from the previous year. Italy followed with 396.5 million euros, experiencing a decline of 1.95%, while Greece witnessed a sharper decrease of 4.92% at 130.0 million euros. Slovakia's sales slightly dipped by 0.042% to 47.7 million euros. Slovenia and Luxembourg saw respective decreases of 2.32% and an increase of 0.21% in their sales, totaling 20.1 and 9.5 million euros.
Future trends to watch for include:
- The growing demand for innovative therapies and personalized medicine may influence market growth positively in major European countries.
- Demographic changes and increased awareness for early diagnosis are likely to drive market expansion, particularly in Germany and Italy.
- Policy changes and healthcare reforms across Europe could play a significant role in shaping both market accessibility and sales trends.
Top countries in Genito Urinary System and Sex Hormones Sales by Country
| # | 6 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 806.3 | 2023 | +0.087% | +0.61% | View data |
| 2 | 2 Italy | 396.5 | 2023 | -2.1% | -1.95% | View data |
| 3 | 3 Greece | 130 | 2023 | -2.77% | -4.92% | View data |
| 4 | 4 Slovakia | 47.7 | 2023 | +0.42% | -0.042% | View data |
| 5 | 5 Slovenia | 20.1 | 2023 | +2.03% | -2.32% | View data |
| 6 | 6 Luxembourg | 9.5 | 2023 | +1.06% | +0.21% | View data |
